Anti-CD123 Immunoconjugate Combinations for Hematological Malignancies
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for hematological malignancies, such as acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm, are inadequate, particularly for relapsed or refractory cases, with limited efficacy and significant toxicity, necessitating the development of more effective therapies.
Innovation Solution
Combining an anti-CD123 immunoconjugate, like IMGN632, with a BCL-2 inhibitor (e.g., venetoclax) and/or a hypomethylating agent (e.g., azacitidine) to target CD123-expressing cancer cells, potentially offering synergistic effects with reduced toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for hematological malignancies are used, then treatment can be administered, but efficacy is limited and toxicity is significant
Solution Approach 1:
The treatment approach is segmented into multiple components: anti-CD123 immunoconjugate (targeted cytotoxic component), BCL-2 inhibitor (apoptosis regulator), and hypomethylating agent (epigenetic modifier). This segmentation allows each component to address specific aspects of cancer cell death while distributing toxicity across different mechanisms, thereby improving overall efficacy while managing harmful effects.
Solution Approach 2:
The patent employs a composite therapeutic regimen combining three distinct mechanisms of action: targeted immunoconjugate delivery, BCL-2 pathway inhibition, and DNA hypomethylation. This composite approach creates synergistic effects where the combination of treatments produces greater antitumor activity than individual therapies, while allowing dose optimization to reduce overall toxicity.
2Reliability
If intensive chemotherapy is administered to improve treatment efficacy, then complete response rates increase, but toxicity increases significantly
Solution Approach 1:
The anti-CD123 immunoconjugate acts as an intermediary that delivers cytotoxic agents specifically to CD123-expressing cancer cells. This targeted delivery mechanism achieves intensive chemotherapy effects in tumor cells while sparing normal tissues, thereby maintaining high complete response rates while reducing off-target toxicity.
Solution Approach 2:
The treatment exhibits local quality through CD123-specific targeting. The immunoconjugate concentrates therapeutic activity specifically in CD123-positive tumor cells, creating high local efficacy where needed while minimizing systemic exposure and toxicity to healthy tissues. This localized action allows intensive dosing at the tumor site without proportionally increasing whole-body toxicity.
Data Source
AI summary
Therapeutic combinations of immunoconjugates that bind to CD123 (e.g., IMGN632) with BCL-2 inhibitors (e.g., venetoclax), and/or a hypomethylating agent (e.g., azacitidine or decitabine) are provided. Methods of administering the combinations to treat hematological malignancies with clinical efficacy and/or decreased toxicity are also provided. Methods of treating hematological malignances present as minimal residual disease using immunoconjugates that bind to CD123 (e.g., IMGN632) are also provided.